Patents Assigned to DMI Biosciences, Inc.
-
Publication number: 20130338166Abstract: The invention provides methods of reducing the side effects of tramadol. Accordingly, in one embodiment, the invention provides a method of reducing the incidence of newly-discovered side effects related to sexual function in human males taking a tramadol material. The method comprises administering a phosphodiesterase inhibitor to a male taking the tramadol material. The invention also provides pharmaceutical compositions. In one embodiment, the composition comprises a tramadol material and a phosphodiesterase inhibitor. The invention further provides kits. In one embodiment, the kit comprises a tramadol material and a phosphodiesterase inhibitor.Type: ApplicationFiled: August 19, 2013Publication date: December 19, 2013Applicant: DMI BioSciences, Inc.Inventors: David Bar-Or, Kevin Bilyard, James V. Winkler
-
Publication number: 20130079284Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: ApplicationFiled: November 16, 2012Publication date: March 28, 2013Applicant: DMI BIOSCIENCES, INC.Inventor: DMI BIOSCIENCES, INC.
-
Publication number: 20130071448Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: ApplicationFiled: November 14, 2012Publication date: March 21, 2013Applicant: DMI BIOSCIENCES, INC.Inventor: DMI Biosciences, Inc.
-
Publication number: 20130071436Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: ApplicationFiled: November 14, 2012Publication date: March 21, 2013Applicant: DMI BIOSCIENCES, INC.Inventor: DMI BIOSCIENCES, INC.
-
Publication number: 20130072684Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: ApplicationFiled: November 14, 2012Publication date: March 21, 2013Applicant: DMI BIOSCIENCES, INC.Inventor: DMI Biosciences, Inc.
-
Publication number: 20130065839Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: ApplicationFiled: November 14, 2012Publication date: March 14, 2013Applicant: DMI BIOSCIENCES, INC.Inventor: DMI BIOSCIENCES, INC
-
Patent number: 8324167Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: GrantFiled: February 18, 2010Date of Patent: December 4, 2012Assignee: DMI Biosciences, Inc.Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
-
Patent number: 8183209Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: GrantFiled: September 28, 2011Date of Patent: May 22, 2012Assignee: DMI Biosciences, Inc.Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkevitz
-
Publication number: 20100249016Abstract: The invention provides a method of reducing the damage done by reactive oxygen species (ROS) in an animal. The invention also provides a method of reducing the concentration of a metal in an animal. These methods comprise administering to the animal an effective amount of a metal-binding compound as further described in the application. The invention further provides a method of reducing the damage done by ROS to a cell, a tissue or an organ that has been removed from an animal. This method comprising contacting the cell, tissue or organ with a solution or medium containing an effective amount of a metal-binding compound of the invention. The invention further provides novel metal-binding compounds, pharmaceutical compositions comprising the metal-binding compounds, and kits comprising a container holding a metal-binding compound of the invention.Type: ApplicationFiled: September 18, 2009Publication date: September 30, 2010Applicant: DMI BIOSCIENCES, INC.Inventors: David Bar-Or, C. Gerald Curtis, Edward Lau, Nagaraja K. R. Rao, James V. Winkler, Wannell M. Crook
-
Patent number: 7732403Abstract: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.Type: GrantFiled: May 14, 2004Date of Patent: June 8, 2010Assignee: DMI Biosciences, Inc.Inventors: David Bar-Or, Raphael Bar-Or, Richard Shimonkovitz
-
Publication number: 20080262094Abstract: The invention provides a method of treating comorbid premature ejaculation and erectile dysfunction. In particular, the method comprises administering an effective amount of a tramadol material and an effective amount of a phosphodiesterase inhibitor. The invention also provides a pharmaceutical composition comprising a pharmaceutically-acceptable carrier, a tramadol material and a phosphodiesterase inhibitor. The invention further provides a kit comprising a tramadol material and a phosphodiesterase inhibitor.Type: ApplicationFiled: February 12, 2008Publication date: October 23, 2008Applicant: DMI BIOSCIENCES, INC.Inventors: James V. Winkler, Kevin Bilyard, David Bar-Or
-
Publication number: 20080261991Abstract: The invention provides methods of reducing the side effects of tramadol. Accordingly, in one embodiment, the invention provides a method of reducing the incidence of newly-discovered side effects related to sexual function in human males taking a tramadol material. The method comprises administering a phosphodiesterase inhibitor to a male taking the tramadol material. The invention also provides pharmaceutical compositions. In one embodiment, the composition comprises a tramadol material and a phosphodiesterase inhibitor. The invention further provides kits. In one embodiment, the kit comprises a tramadol material and a phosphodiesterase inhibitor.Type: ApplicationFiled: February 12, 2008Publication date: October 23, 2008Applicant: DMI BIOSCIENCES, INC.Inventors: David Bar-Or, Kevin Bilyard, James V. Winkler
-
Publication number: 20080167376Abstract: The invention provides therapeutic methods and products for the treatment of inflammation, inflammatory diseases and conditions, and proliferative diseases and conditions. The invention also provides methods and products for inhibiting inflammation in excised cells, tissues and organs. The invention further provides oral care methods and products for the treatment of the tissues of an animal's mouth. Finally, the invention provides personal care methods and products for the treatment of the skin of an animal. All of these methods and products utilize N-acyl-L-aspartic acid or an ester or pharmaceutically-acceptable salt thereof.Type: ApplicationFiled: December 28, 2007Publication date: July 10, 2008Applicant: DMI BIOSCIENCES, INC.Inventors: David Bar-Or, Leonard T. Rael
-
Publication number: 20070111972Abstract: The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.Type: ApplicationFiled: July 12, 2006Publication date: May 17, 2007Applicant: DMI BIOSCIENCES, INC.Inventor: David Bar-Or
-
Patent number: 6974839Abstract: The invention provides a method of delaying ejaculation. The method comprises administering an effective amount of a tramadol material to a human male prior to sexual intercourse. The method is particularly useful for treating premature ejaculation.Type: GrantFiled: March 15, 2002Date of Patent: December 13, 2005Assignee: DMI BioSciences, Inc.Inventor: David Bar-Or
-
Patent number: 6967202Abstract: The invention provides a method of synthesizing a diketopiperazine of the formula: wherein: R1 is —CH2COR3, or —CH2CH2COR3; R2 is the side chain of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, phenylalanine, tyrosine, tryptophan, thyroxine, cysteine, methionine, norvaline and ornithine; R3 is —OH, —NH2, —OR4, —NHR4, or —NR4R4; and each R4 is independently an alkyl, aryl, alkylaryl, or arylalkyl.Type: GrantFiled: August 2, 2001Date of Patent: November 22, 2005Assignee: DMI Biosciences, Inc.Inventors: Nagaraja K. R. Rao, Stephen Turner
-
Publication number: 20030225103Abstract: The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells.Type: ApplicationFiled: March 25, 2003Publication date: December 4, 2003Applicant: DMI BioSciences, Inc.Inventors: David Bar-Or, C. Gerald Curtis, Nagaraja K.R. Rao, Greg Thomas
-
Patent number: 6615162Abstract: A noise reduction/resolution enhancement signal processing method and system is disclosed, wherein the influence of noise spikes and gaps is substantially reduced. The data for the noise reduction may be amplitudes (bx) measured at corresponding values (x) over a given domain D, wherein the data defines a composite wave form. The composite wave form is decomposed into instances of a discrete wave form, each having reduced noise amplitudes. A candidate point c in D for, e.g., an amplitude extreme is determined for each discrete wave form instance (having unknown amplitude). A minimization technique determines a first set of discrete wave form instances (having known amplitudes) by collapsing on the amplitudes (bx) from above. A maximization technique determines a second set of discrete wave form instances (having known amplitudes) by rising up to the amplitudes (bx) from below.Type: GrantFiled: December 6, 2000Date of Patent: September 2, 2003Assignee: DMI BioSciences, Inc.Inventor: Raphael Bar-Or
-
Patent number: 6555543Abstract: The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: wherein R1 and R2 are defined in the application, or a physiologically-acceptable salt thereof. The invention also provides pharmaceutical compositions comprising these compounds.Type: GrantFiled: August 2, 2001Date of Patent: April 29, 2003Assignee: DMI BioSciences, Inc.Inventors: David Bar-Or, C. Gerald Curtis, Nagaraja K. R. Rao, Greg Thomas